Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Weibo Corp — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Weibo Corp trades at $6.46 (market cap $1.57B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 81.6× Weibo Corp's market cap, and Weibo Corp pays a 9.41% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Weibo Corp for 102 Days on average.
| VRTX | WB | |
|---|---|---|
Market Cap | $128.16B | $1.57B |
Volume | 806,603 | 947,144 |
Sector | Health | Media |
52-Week High | $557.96 | $12.37 |
52-Week Low | $407.37 | $6.33 |
Typical Hold Time | 120 Days | 102 Days |
Enterprise Value | $122.29B | $799.15M |
Dividend Yield | — | 9.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Weibo (WB) trades at $6.44, down 0.77% on the day, with a bearish technical signal from moving averages. The stock shows attractive valuation metrics with a P/E of 5.36 and P/B of 0.4, while maintaining strong profitability with 73.36% gross margins and 17.78% net income margin. Recent Q2 2026 earnings beat expectations with $0.38 EPS versus $0.36 expected, though Q1 and Q4 2025 missed estimates. Cash flow trends show volatility, with 2024 net cash flow negative $694 million but improving to positive $408 million in 2025.
Weibo presents a deep-value opportunity with compelling valuation multiples, though growth concerns persist amid declining user metrics and advertising revenue challenges. Analyst sentiment remains mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance against intensifying competition. Key risks include stagnating user growth and advertising market pressures, while the current price offers margin of safety for value-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
